Showing 81 - 100 results of 18,078 for search '(( significant larger decrease ) OR ( significant ((we decrease) OR (a decrease)) ))', query time: 0.57s Refine Results
  1. 81
  2. 82
  3. 83

    <i>Aedes aegypti</i> database from SAGO traps. by Jesús A. Aguilar-Durán (9931967)

    Published 2025
    “…IVM treatment reduced the number of females per trap per week from 3.29 ± 0.24 to 2.41 ± 0.20 (33.7% reduction), AGO from 1.58 ± 0.17 to 0.25 ± 0.05 (85.2% reduction), and AGO + IVM from 1.49 ± 0.17 to 0.53 ± 0.08 (67.78% reduction), based on Henderson’s formula. We observed a non-significant increase in the control area (no treatment provided) in the mosquito populations, increasing from 2.94 ± 0.24 in the pretreatment period to 3.25 ± 0.28 of the post treatment period.…”
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88

    Scheme of g-λ model with larger values λ. by Zhanfeng Fan (20390992)

    Published 2024
    “…The findings suggest that when λ is respectively equal to 4.19, 8.57, 10, and 12.15, the peak particle velocity (PPV) of the transmitted waves is significantly close to the incident wave amplitude. Furthermore, when λ is fixed, the energy transmission coefficient increases with the incident wave amplitude but decreases with the incident wave frequency. …”
  9. 89
  10. 90

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  11. 91

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  12. 92

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  13. 93
  14. 94

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…In addition, genetic variation in age-related plasticity in exploration contributed to a decrease in the magnitude of genetic correlations during the adult stage. …”
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100